NeoGenomics Stock Price, News & Analysis (NASDAQ:NEO)

$9.06 -0.05 (-0.55 %)
(As of 12/14/2017 04:00 PM ET)
Previous Close$9.06
Today's Range$8.79 - $9.14
52-Week Range$7.12 - $11.63
Volume365,326 shs
Average Volume344,937 shs
Market Capitalization$739.77 million
P/E Ratio184
Dividend YieldN/A
Beta0.85

About NeoGenomics (NASDAQ:NEO)

NeoGenomics logoNeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee. It offers testing services, which include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Immunohistochemistry (IHC), Molecular testing and Pathology consultation. Its Pharma Services and Clinical Trials group provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.

Receive NEO News and Ratings via Email

Sign-up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical & Diagnostic Laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NEO
CUSIPN/A
Phone239-768-0600

Debt

Debt-to-Equity Ratio0.57%
Current Ratio2.14%
Quick Ratio1.99%

Price-To-Earnings

Trailing P/E Ratio184
Forward P/E Ratio226.50
P/E Growth11.5

Sales & Book Value

Annual Sales$244.08 million
Price / Sales2.98
Cash Flow$0.45 per share
Price / Cash20.25
Book Value$2.09 per share
Price / Book4.33

Profitability

Trailing EPS($0.35)
Net Income$-5,720,000.00
Net Margins-4.78%
Return on Equity3.97%
Return on Assets1.95%

Miscellaneous

Employees968
Outstanding Shares80,410,000

NeoGenomics (NASDAQ:NEO) Frequently Asked Questions

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) posted its quarterly earnings results on Wednesday, October, 25th. The medical research company reported $0.01 earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of $0.01. The medical research company had revenue of $63.05 million for the quarter, compared to analyst estimates of $63.11 million. NeoGenomics had a negative net margin of 4.78% and a positive return on equity of 3.97%. The company's quarterly revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.04 earnings per share. View NeoGenomics' Earnings History.

When will NeoGenomics make its next earnings announcement?

NeoGenomics is scheduled to release their next quarterly earnings announcement on Wednesday, February, 21st 2018. View Earnings Estimates for NeoGenomics.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics updated its fourth quarter earnings guidance on Wednesday, October, 25th. The company provided earnings per share (EPS) guidance of $0.04-0.05 for the period, compared to the Thomson Reuters consensus estimate of $0.04. The company issued revenue guidance of $65-67 million, compared to the consensus revenue estimate of $66.11 million.

Where is NeoGenomics' stock going? Where will NeoGenomics' stock price be in 2017?

4 equities research analysts have issued twelve-month price objectives for NeoGenomics' stock. Their forecasts range from $9.00 to $11.00. On average, they anticipate NeoGenomics' share price to reach $10.33 in the next year. View Analyst Ratings for NeoGenomics.

What are Wall Street analysts saying about NeoGenomics stock?

Here are some recent quotes from research analysts about NeoGenomics stock:

  • 1. According to Zacks Investment Research, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States. " (10/26/2017)
  • 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating and $11 price target following last week's meeting with management. The company highlighted the strategic benefits of its tech-only offering, the Clarient acquisition, positive secular trends that are driving cancer diagnostics, and NEO's strong management team. The biggest takeaway, in our view, was that the Clarient integration continues to progress, which should drive further cost synergies as well as revenue synergies. We estimate that there is a $10-16M low-hanging revenue opportunity from targeting 100 Clarient accounts. We believe that the company will be able to unlock 25-40% of these and, thus, we are modeling $4-6M of revenue synergies ($2-3M in EBITDA contribution), with significant potential upside." (3/22/2017)

Who are some of NeoGenomics' key competitors?

Who are NeoGenomics' key executives?

NeoGenomics' management team includes the folowing people:

  • Douglas M. VanOort, Chairman of the Board, Chief Executive Officer (Age 61)
  • George A. Cardoza, Chief Financial Officer (Age 55)
  • Robert J. Shovlin, President - Clinical Services Division (Age 44)
  • Steven C. Jones, Executive Vice President, Chief Compliance Officer, Director (Age 54)
  • Kathryn McKenzie, Principal Accounting Officer, Vice President - Finance (Age 33)
  • Steven A. Ross, Chief Information Officer (Age 53)
  • Steven G. Brodie Ph.d., Vice President - Operations (Age 55)
  • Jennifer M. Balliet, Vice President - Human Resources (Age 40)
  • Maher Albitar M.D., Chief Medical Officer, Director - Research and Development (Age 62)
  • Stephen Michael Kanovsky, Director

Who owns NeoGenomics stock?

NeoGenomics' stock is owned by many different of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (4.36%), Russell Investments Group Ltd. (3.14%), Artisan Partners Limited Partnership (2.94%), Emerald Advisers Inc. PA (1.74%), Summit Creek Advisors LLC (1.43%) and Emerald Mutual Fund Advisers Trust (1.41%). Company insiders that own NeoGenomics stock include Alison L Hannah, George Cardoza, Jennifer Balliet, Maher Albitar, Oort Douglas M Van, Steven A Ross, Steven C Jones and Steven G Brodie. View Institutional Ownership Trends for NeoGenomics.

Who sold NeoGenomics stock? Who is selling NeoGenomics stock?

NeoGenomics' stock was sold by a variety of institutional investors in the last quarter, including Northpointe Capital LLC, Gabelli Funds LLC, Cowen Prime Services LLC, Suffolk Capital Management LLC, Dimensional Fund Advisors LP, Gamco Investors INC. ET AL, Strs Ohio and Artisan Partners Limited Partnership. Company insiders that have sold NeoGenomics company stock in the last year include Jennifer Balliet, Steven A Ross and Steven G Brodie. View Insider Buying and Selling for NeoGenomics.

Who bought NeoGenomics stock? Who is buying NeoGenomics stock?

NeoGenomics' stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Russell Investments Group Ltd., Columbus Circle Investors, Segall Bryant & Hamill LLC, EAM Investors LLC, Emerald Mutual Fund Advisers Trust, Emerald Advisers Inc. PA and New York State Common Retirement Fund. View Insider Buying and Selling for NeoGenomics.

How do I buy NeoGenomics stock?

Shares of NeoGenomics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NeoGenomics' stock price today?

One share of NeoGenomics stock can currently be purchased for approximately $9.06.

How big of a company is NeoGenomics?

NeoGenomics has a market capitalization of $739.77 million and generates $244.08 million in revenue each year. The medical research company earns $-5,720,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. NeoGenomics employs 968 workers across the globe.

How can I contact NeoGenomics?

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]


MarketBeat Community Rating for NeoGenomics (NEO)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  195 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  315
MarketBeat's community ratings are surveys of what our community members think about NeoGenomics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

NeoGenomics (NASDAQ:NEO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.672.78
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $10.67$10.67$10.57$10.86
Price Target Upside: 33.00% upside33.00% upside0.64% downside47.12% upside

NeoGenomics (NASDAQ:NEO) Consensus Price Target History

Price Target History for NeoGenomics (NASDAQ:NEO)

NeoGenomics (NASDAQ:NEO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/26/2017Janney Montgomery ScottReiterated RatingBuyN/AView Rating Details
9/11/2017BTIG ResearchDowngradeBuy -> NeutralHighView Rating Details
8/24/2017GabelliInitiated CoverageBuy$9.00HighView Rating Details
5/27/2017Cantor FitzgeraldSet Price TargetBuy$11.00N/AView Rating Details
11/16/2016Axiom SecuritiesReiterated RatingHold -> SellN/AView Rating Details
10/3/2016First AnalysisInitiated CoverageOverweight$11.00N/AView Rating Details
9/8/2016Raymond James FinancialInitiated CoverageOutperform$10.00N/AView Rating Details
7/27/2016BenchmarkBoost Price TargetBuy$10.00 -> $12.00N/AView Rating Details
7/9/2016Craig HallumReiterated RatingBuyN/AView Rating Details
5/11/2016Roth CapitalInitiated CoverageBuy$10.00N/AView Rating Details
(Data available from 12/14/2015 forward)

Earnings

NeoGenomics (NASDAQ:NEO) Earnings History and Estimates Chart

Earnings by Quarter for NeoGenomics (NASDAQ:NEO)

NeoGenomics (NASDAQ NEO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2018$0.04N/AView Earnings Details
10/25/2017Q3 2017$0.01$0.01$63.11 million$63.05 millionViewN/AView Earnings Details
7/25/2017Q2 2017$0.01$0.04$62.95 million$66.09 millionViewN/AView Earnings Details
4/26/2017Q1 2017$0.01$0.03$61.26 million$61.68 millionViewN/AView Earnings Details
2/22/2017Q416$0.03$0.05$61.83 million$60.50 millionViewListenView Earnings Details
10/26/2016Q316$0.03$0.04$61.00 million$60.76 millionViewListenView Earnings Details
7/26/2016Q216$0.03$0.04$61.07 million$63.10 millionViewListenView Earnings Details
4/27/2016Q116($0.07)$0.03$57.00 million$59.70 millionViewListenView Earnings Details
3/1/2016Q415$0.02($0.03)$26.46 million$27.30 millionViewN/AView Earnings Details
4/28/2015Q115($0.02)($0.01)$23.36 million$23.00 millionViewN/AView Earnings Details
2/24/2015Q414$0.01$0.02$24.30 million$25.00 millionViewN/AView Earnings Details
10/30/2014Q314($0.01)$0.01$22.43 million$23.20 millionViewN/AView Earnings Details
7/17/2014Q214$0.01$0.01$19.84 million$20.70 millionViewN/AView Earnings Details
2/19/2014Q413$0.02$0.04$17.80 million$18.30 millionViewN/AView Earnings Details
10/23/2013Q313$0.01$0.02$16.84 million$16.90 millionViewN/AView Earnings Details
7/31/2013Q2 2013$0.01$16.20 million$15.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

NeoGenomics (NASDAQ:NEO) Earnings Estimates

2017 EPS Consensus Estimate: $0.01
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q4 20171$0.01$0.01$0.01
Q3 20181$0.02$0.02$0.02
Q4 20181$0.02$0.02$0.02
(Data provided by Zacks Investment Research)

Dividends

Dividend History for NeoGenomics (NASDAQ:NEO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

NeoGenomics (NASDAQ NEO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.20%
Institutional Ownership Percentage: 83.73%
Insider Trades by Quarter for NeoGenomics (NASDAQ:NEO)
Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

NeoGenomics (NASDAQ NEO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/27/2017Alison L HannahDirectorBuy20,000$9.19$183,800.00View SEC Filing  
6/22/2017Jennifer BallietVPSell10,723$8.49$91,038.27View SEC Filing  
6/5/2017Steven A RossInsiderSell70,833$7.76$549,664.08View SEC Filing  
5/26/2017Jennifer BallietVPSell3,334$7.50$25,005.00View SEC Filing  
3/20/2017Steven G BrodieInsiderSell50,000$7.93$396,500.00View SEC Filing  
9/23/2016Maher AlbitarInsiderSell2,800$8.40$23,520.00View SEC Filing  
9/20/2016Maher AlbitarInsiderSell105,300$8.20$863,460.00View SEC Filing  
9/12/2016Maher AlbitarInsiderSell60,075$8.23$494,417.25View SEC Filing  
8/19/2016Maher AlbitarInsiderSell370,000$8.23$3,045,100.00View SEC Filing  
5/27/2016Oort Douglas M VanCEOSell481,387$8.73$4,202,508.51View SEC Filing  
5/18/2016Steven A RossInsiderSell18,000$8.50$153,000.00View SEC Filing  
5/9/2016Steven A RossInsiderSell15,000$8.22$123,300.00View SEC Filing  
5/2/2016Steven C JonesVPSell177,745$8.21$1,459,286.45View SEC Filing  
4/29/2016Steven A RossInsiderSell112,500$8.11$912,375.00View SEC Filing  
3/11/2016George CardozaCFOSell32,000$6.83$218,560.00View SEC Filing  
3/9/2016Oort Douglas M VanCEOSell450,000$7.10$3,195,000.00View SEC Filing  
3/3/2016Alison L HannahDirectorBuy10,000$6.90$69,000.00View SEC Filing  
12/7/2015Lynn A TetraultDirectorBuy3,500$7.72$27,020.00View SEC Filing  
12/3/2015Robert J ShovlinCOOBuy6,550$7.75$50,762.50View SEC Filing  
11/27/2015Steven C JonesVPSell385,000$8.09$3,114,650.00View SEC Filing  
11/2/2015Bruce K CrowtherDirectorBuy6,400$7.81$49,984.00View SEC Filing  
12/19/2014Robert H HorelVPSell32,389$4.21$136,357.69View SEC Filing  
12/18/2014Robert H HorelVPSell62,893$4.20$264,150.60View SEC Filing  
12/4/2014Michael T DentDirectorSell11,800$4.50$53,100.00View SEC Filing  
11/26/2014George CardozaCFOSell60,000$4.28$256,800.00View SEC Filing  
11/21/2014Michael T DentDirectorSell33,200$4.51$149,732.00View SEC Filing  
5/22/2014Robert P GaspariniInsiderSell100,000$3.49$349,000.00View SEC Filing  
5/19/2014Robert GaspariniInsiderSell10,000$3.65$36,500.00View SEC Filing  
3/28/2014Maher AlbitarInsiderBuy14,492$3.51$50,866.92View SEC Filing  
3/5/2014Michael T DentDirectorSell300,000$3.00$900,000.00View SEC Filing  
12/11/2013Robert P GaspariniInsiderSell20,100$3.70$74,370.00View SEC Filing  
12/9/2013George CardozaCFOSell20,000$3.66$73,200.00View SEC Filing  
12/5/2013Robert P GaspariniInsiderSell32,996$3.67$121,095.32View SEC Filing  
12/3/2013Robert P GaspariniInsiderSell32,146$3.67$117,975.82View SEC Filing  
11/25/2013Steven C JonesVPSell112,969$3.58$404,429.02View SEC Filing  
4/30/2013Steven C JonesDirectorSell100,000$3.71$371,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

NeoGenomics (NASDAQ NEO) News Headlines

Source:
DateHeadline
NeoGenomics, Inc. breached its 50 day moving average in a Bearish Manner : NEO-US : December 14, 2017NeoGenomics, Inc. breached its 50 day moving average in a Bearish Manner : NEO-US : December 14, 2017
finance.yahoo.com - December 14 at 9:30 AM
NeoGenomics, Inc. (NEO) Given Average Recommendation of "Buy" by AnalystsNeoGenomics, Inc. (NEO) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 7 at 10:00 PM
NeoGenomics (NEO) Announces Six Clinical Data Presentations at ASH - StreetInsider.comNeoGenomics (NEO) Announces Six Clinical Data Presentations at ASH - StreetInsider.com
www.streetinsider.com - December 7 at 5:56 PM
NeoGenomics (NEO) Announces Six Clinical Data Presentations at ASHNeoGenomics (NEO) Announces Six Clinical Data Presentations at ASH
www.streetinsider.com - December 6 at 9:30 AM
NeoGenomics Announces Six Clinical Data Presentations to be Made at the American Society of Hematology MeetingNeoGenomics Announces Six Clinical Data Presentations to be Made at the American Society of Hematology Meeting
finance.yahoo.com - December 6 at 9:30 AM
NeoGenomics Joins Thermo Fisher Scientifics Companion Diagnostic Center of Excellence Program with the Launch of Oncomine Dx Target TestNeoGenomics Joins Thermo Fisher Scientific's Companion Diagnostic Center of Excellence Program with the Launch of Oncomine Dx Target Test
finance.yahoo.com - December 5 at 10:01 AM
FY2017 Earnings Estimate for NeoGenomics, Inc. Issued By Gabelli (NEO)FY2017 Earnings Estimate for NeoGenomics, Inc. Issued By Gabelli (NEO)
www.americanbankingnews.com - December 4 at 1:26 AM
Zacks: Analysts Expect NeoGenomics, Inc. (NEO) to Post $0.04 EPSZacks: Analysts Expect NeoGenomics, Inc. (NEO) to Post $0.04 EPS
www.americanbankingnews.com - November 22 at 7:10 PM
NeoGenomics, Inc. to Post FY2017 Earnings of $0.02 Per Share, William Blair Forecasts (NEO)NeoGenomics, Inc. to Post FY2017 Earnings of $0.02 Per Share, William Blair Forecasts (NEO)
www.americanbankingnews.com - November 20 at 3:15 AM
See what the IHS Markit Score report has to say about Neogenomics Inc.See what the IHS Markit Score report has to say about Neogenomics Inc.
finance.yahoo.com - November 18 at 7:08 AM
Brokers Set Expectations for NeoGenomics, Inc.s Q3 2018 Earnings (NEO)Brokers Set Expectations for NeoGenomics, Inc.'s Q3 2018 Earnings (NEO)
www.americanbankingnews.com - November 18 at 12:22 AM
NeoGenomics, Inc. (NEO) Given Consensus Recommendation of "Hold" by AnalystsNeoGenomics, Inc. (NEO) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 12 at 10:38 PM
NeoGenomics Europe S.A. Opens its Doors in Rolle, Switzerland Laboratory Hosting Business Leaders, Dignitaries and Local Government OfficialsNeoGenomics Europe S.A. Opens its Doors in Rolle, Switzerland Laboratory Hosting Business Leaders, Dignitaries and Local Government Officials
finance.yahoo.com - November 9 at 7:43 AM
NeoGenomics, Inc. (NEO) Expected to Post Earnings of $0.04 Per ShareNeoGenomics, Inc. (NEO) Expected to Post Earnings of $0.04 Per Share
www.americanbankingnews.com - November 3 at 1:38 PM
Clinical Laboratory Services Market: Companies Focus on Technological ...Clinical Laboratory Services Market: Companies Focus on Technological ...
www.prnewswire.com - November 1 at 6:42 AM
Edited Transcript of NEO earnings conference call or presentation 25-Oct-17 2:00pm GMTEdited Transcript of NEO earnings conference call or presentation 25-Oct-17 2:00pm GMT
finance.yahoo.com - October 27 at 8:26 AM
NeoGenomics, Inc. (NEO) Receives Buy Rating from Janney Montgomery ScottNeoGenomics, Inc. (NEO) Receives Buy Rating from Janney Montgomery Scott
www.americanbankingnews.com - October 26 at 10:30 AM
NeoGenomics, Inc. (NEO) Announces  Earnings Results, Misses Expectations By $0.01 EPSNeoGenomics, Inc. (NEO) Announces Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - October 25 at 10:33 AM
NeoGenomics, Inc. (NEO) Updates Q4 Earnings GuidanceNeoGenomics, Inc. (NEO) Updates Q4 Earnings Guidance
www.americanbankingnews.com - October 25 at 9:50 AM
BRIEF-NeoGenomics reports Q3 adj earnings per share of $0.01BRIEF-NeoGenomics reports Q3 adj earnings per share of $0.01
www.reuters.com - October 25 at 8:05 AM
NeoGenomics Announces the Opening of its First International Laboratory near Geneva, Switzerland to Support Clinical TrialsNeoGenomics Announces the Opening of its First International Laboratory near Geneva, Switzerland to Support Clinical Trials
finance.yahoo.com - October 25 at 8:05 AM
ETFs with exposure to NeoGenomics, Inc. : October 24, 2017ETFs with exposure to NeoGenomics, Inc. : October 24, 2017
finance.yahoo.com - October 25 at 8:05 AM
Investor Network Invites You to the NeoGenomics Third Quarter 2017 Earnings Conference Call and Webcast Live on Wednesday, October 25, 2017Investor Network Invites You to the NeoGenomics Third Quarter 2017 Earnings Conference Call and Webcast Live on Wednesday, October 25, 2017
finance.yahoo.com - October 25 at 8:05 AM
NeoGenomics, Inc. to Host Earnings CallNeoGenomics, Inc. to Host Earnings Call
finance.yahoo.com - October 25 at 8:04 AM
NeoGenomics reports 3Q lossNeoGenomics reports 3Q loss
finance.yahoo.com - October 25 at 8:04 AM
NeoGenomics Reports Revenue of $63.1 Million on 17% Volume Growth and 11% Reduction in Average Cost per Test in the Third Quarter of 2017NeoGenomics Reports Revenue of $63.1 Million on 17% Volume Growth and 11% Reduction in Average Cost per Test in the Third Quarter of 2017
feeds.benzinga.com - October 25 at 8:04 AM
NeoGenomics, Inc. (NEO) Raised to "Hold" at Zacks Investment ResearchNeoGenomics, Inc. (NEO) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - October 21 at 11:16 PM
Form 4 NEOGENOMICS INC For: Oct 18 Filed by: McKenzie Kathryn BForm 4 NEOGENOMICS INC For: Oct 18 Filed by: McKenzie Kathryn B
www.streetinsider.com - October 21 at 6:58 AM
Form 4 NEOGENOMICS INC For: Oct 18 Filed by: McKenzie Kathryn BForm 4 NEOGENOMICS INC For: Oct 18 Filed by: McKenzie Kathryn B
www.streetinsider.com - October 21 at 6:58 AM
NeoGenomics, Inc. (NEO) Given Consensus Rating of "Hold" by BrokeragesNeoGenomics, Inc. (NEO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - October 19 at 12:38 AM
Oversold Conditions For NeoGenomics (NEO)Oversold Conditions For NeoGenomics (NEO)
www.thestreet.com - October 18 at 7:30 AM
$64.69 Million in Sales Expected for NeoGenomics, Inc. (NEO) This Quarter$64.69 Million in Sales Expected for NeoGenomics, Inc. (NEO) This Quarter
www.americanbankingnews.com - October 17 at 9:52 AM
NeoGenomics, Inc. (NEO) Scheduled to Post Earnings on TuesdayNeoGenomics, Inc. (NEO) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - October 17 at 4:32 AM
NeoGenomics, Inc. breached its 50 day moving average in a Bearish Manner : NEO-US : October 16, 2017NeoGenomics, Inc. breached its 50 day moving average in a Bearish Manner : NEO-US : October 16, 2017
finance.yahoo.com - October 17 at 2:10 AM
$0.03 Earnings Per Share Expected for NeoGenomics, Inc. (NEO) This Quarter$0.03 Earnings Per Share Expected for NeoGenomics, Inc. (NEO) This Quarter
www.americanbankingnews.com - October 15 at 2:06 AM
NeoGenomics, Inc. (NEO) Upgraded by Zacks Investment Research to "Hold"NeoGenomics, Inc. (NEO) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - October 14 at 3:22 PM
NeoGenomics (NEO) Reports Prelim. Q3 Revenue of $63.1MNeoGenomics (NEO) Reports Prelim. Q3 Revenue of $63.1M
www.streetinsider.com - October 14 at 6:07 AM
BRIEF-NeoGenomics sees Q3 revenue of about $63.1 mlnBRIEF-NeoGenomics sees Q3 revenue of about $63.1 mln
www.reuters.com - October 14 at 6:07 AM
ETFs with exposure to NeoGenomics, Inc. : October 13, 2017ETFs with exposure to NeoGenomics, Inc. : October 13, 2017
finance.yahoo.com - October 14 at 6:07 AM
NeoGenomics (NEO) Reports Prelim. Q3 Revenue of $63.1M - StreetInsider.comNeoGenomics (NEO) Reports Prelim. Q3 Revenue of $63.1M - StreetInsider.com
www.streetinsider.com - October 13 at 7:18 AM
NeoGenomics Announces Preliminary Quarter 3 Results, Financial Impacts of Hurricanes and Summary Quarter 4 GuidanceNeoGenomics Announces Preliminary Quarter 3 Results, Financial Impacts of Hurricanes and Summary Quarter 4 Guidance
finance.yahoo.com - October 13 at 7:18 AM
NeoGenomics, Inc. (NEO) Stock Rating Lowered by Zacks Investment ResearchNeoGenomics, Inc. (NEO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - October 8 at 1:06 PM
Anatomic Pathology Market Revenue to Reach US$30,314.5 Million by 2025 Globally: Transparency Market ResearchAnatomic Pathology Market Revenue to Reach US$30,314.5 Million by 2025 Globally: Transparency Market Research
www.prnewswire.com - October 5 at 11:02 AM
NeoGenomics Schedules its Q3 2017 Earnings Release for October 25, 2017NeoGenomics Schedules its Q3 2017 Earnings Release for October 25, 2017
finance.yahoo.com - October 2 at 5:51 PM
NeoGenomics, Inc. :NEO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017NeoGenomics, Inc. :NEO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017
finance.yahoo.com - October 2 at 5:51 PM
ETFs with exposure to NeoGenomics, Inc. : October 2, 2017ETFs with exposure to NeoGenomics, Inc. : October 2, 2017
finance.yahoo.com - October 2 at 5:51 PM
 Brokerages Expect NeoGenomics, Inc. (NEO) Will Post Earnings of $0.04 Per Share Brokerages Expect NeoGenomics, Inc. (NEO) Will Post Earnings of $0.04 Per Share
www.americanbankingnews.com - September 26 at 10:10 AM
NeoGenomics, Inc. (NEO) Given Average Rating of "Buy" by BrokeragesNeoGenomics, Inc. (NEO) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 23 at 10:48 PM
NeoGenomics Reports on Impacts from Hurricane IrmaNeoGenomics Reports on Impacts from Hurricane Irma
feeds.benzinga.com - September 11 at 4:35 PM
NeoGenomics, Inc. (NEO) Downgraded by BTIG Research to NeutralNeoGenomics, Inc. (NEO) Downgraded by BTIG Research to Neutral
www.americanbankingnews.com - September 11 at 8:10 AM

SEC Filings

NeoGenomics (NASDAQ:NEO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

NeoGenomics (NASDAQ:NEO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

NeoGenomics (NASDAQ NEO) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.